Jalid Sehouli

Research interests

Publications

• ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025

  The Lancet Oncology · 2025 · 10.1016/s1470-2045(25)00167-6

• ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2023.11.015

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

  The Lancet · 2024 · 10.1016/s0140-6736(24)00317-9

• Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.02132

• Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

  Annals of Oncology · 2023 · 10.1016/j.annonc.2023.05.005

• Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

  Journal of Clinical Oncology · 2021 · 10.1200/jco.21.00306

• ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

  International Journal of Gynecological Cancer · 2020 · https://doi.org/10.1136/ijgc-2020-002230

• Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

  Annals of Oncology · 2019 · 10.1093/annonc/mdz135

• Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911361

• A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1808424

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz062

• Ovarian cancer

  Nature Reviews Disease Primers · 2016 · https://doi.org/10.1038/nrdp.2016.61

• The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids

  Nature Communications · 2015 · 10.1038/ncomms9989

• ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv484

• Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/dju426

• Contemporary management of endometrial cancer

  The Lancet · 2012 · 10.1016/s0140-6736(12)60442-5

• The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds203

• Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

  International Journal of Gynecological Cancer · 2011 · 10.1097/igc.0b013e31820aaafd

• A Phase 3 Trial of Bevacizumab in Ovarian Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103799

• Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.7519

• Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes

  Cancer Letters · 2009 · 10.1016/j.canlet.2008.12.028

• Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM

  Gynecologic Oncology · 2007 · 10.1016/j.ygyno.2007.08.064

• Magnetic nanoparticles for interstitial thermotherapy – feasibility, tolerance and achieved temperatures

  International Journal of Hyperthermia · 2006 · 10.1080/02656730601106037

• Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

  Annals of Surgical Oncology · 2006 · https://doi.org/10.1245/s10434-006-9058-0

• Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors

  Cancer Research · 2006 · 10.1158/0008-5472.can-06-0755

• Systematic review and meta-analysis of antibiotic therapy for bone and joint infections

  The Lancet Infectious Diseases · 2001 · 10.1016/s1473-3099(01)00094-9

Current projects

No projects listed.